[Interchangeability and substitution of biosimilars]. / Interchangeabilité et substitution des biosimilaires.
Ann Pharm Fr
; 78(4): 277-284, 2020 Jul.
Article
em Fr
| MEDLINE
| ID: mdl-32387176
ABSTRACT
The rationality of the interchangeability of biosimilars is based on broad scientific evidence and numerous clinical experiences in real life which show no sign of reduced efficacy or different tolerance compared to the original molecule. The substitution of biosimilars (pharmaceutical act) remains widely contested in many countries, notably in France. However, it would make it possible to make very significant savings in a context of major acceleration in health spending. This reluctance is unfounded in light of the quality of biosimilars authorized in Europe and their rigorous evaluation. It is therefore essential to improve the information of health professionals and patients on these biosimilars.
Palavras-chave
Texto completo:
1
Coleções:
01-internacional
Base de dados:
MEDLINE
Assunto principal:
Substituição de Medicamentos
/
Medicamentos Biossimilares
Limite:
Humans
País/Região como assunto:
Europa
Idioma:
Fr
Revista:
Ann Pharm Fr
Ano de publicação:
2020
Tipo de documento:
Article